Therapies for unmet chronic inflammatory diseases READ MORE A new Clinical Stage Biopharma Company founded by seasoned entrepreneurs in Life Science READ MORE Two peptides acting in the JNK inhibition READ MORE

Kuste Biopharma

Develop therapies for unmet medical inflammatory urological diseases

Objective

Develop therapies for unmet medical inflammatory urological diseases such as Interstitial Cystitis/Painful Bladder Syndrome.

Development

Two small peptides acting in the JNK inhibition, have reached up to Phase 3 results.

Press releases

Read more about KUSTE BIOPHARMA in the medias and check our press releases.

Proprietary molecules

10+ years extensively studied, proven safe and efficacious JNK inhibitors for a variety of therapeutic applications.

JNK INHIBITION

Inhibitors of the JNK pathway have a proven therapeutic impact in the treatment of inflammatory diseases.

Launching studies

Launching clinical studies for the unmet clinical need of IC/PBS and preclinical on other inflammatory pathologies e.g. IBD

Discover the team

Governance

Read more about our Scientific Advisory Board and Management Team…

Kuste Biopharma

2 bis rue Tête d’Or
69006 Lyon

5 rue de Castiglione
75001 Paris

+33 (0) 481 133 530
contact@kustebiopharma.com

http://Logo-kuste-Biopharma-Vertical-desktop
Retour haut de page